Genix Pharmaceuticals Corporation (TSXV:GENX) entered into a definitive agreement to acquire global distribution, sales and marketing rights and interest for Flu-X(r) from Canagen Pharmaceuticals Inc. for CAD 0.1 million on March 24, 2020. Under the Agreement, the Company will acquire the Global Rights for a term of ten years, extendable by mutual agreement, by making cash payments to Canagen of CAD 0.1 million, comprising CAD 0.03 million paid within four months of closing, and CAD 0.08 within the first anniversary thereafter. The transaction is subject to acceptance of the TSX Venture Exchange. As per filing on September 28, 2020, Canagen has been paid the first installment of CAD 25,000. The final installment of CAD 75,000 is due on September 21, 2021. As of September 22, 2021, the final payment deadline has been extended to December 31, 2021, as agreed to in writing by both parties. Genix Pharmaceuticals Corporation (TSXV:GENX) completed the acquisition of global distribution, sales and marketing rights and interest for Flu-X(r) from Canagen Pharmaceuticals Inc. on September 28, 2020.